Signals, Powered By EquityPandit
Dr Reddy’s Laboratories has launched generic Paricalcitol injection which is used in the treatment associated with chronic kidney disease in the US.
It has said in a BSE filing that the firm has launched the injection USP in the strengths of 2 mcg, 5 mcg and 10 mcg.
It further said that the company’s product is generic version of AbbVie Inc’s Zemplar injections.
According to it, the injection is first Abbreviated New Drug Application (ANDA) product launched in the US after approval from the US Food and Drug Administration.
